Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ: GILD )

90.19 +0.43 (+0.48%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Gilead Sciences

< Previous 1 2
...
28 29 30 31 32 33 34 35 36
...
52 53 Next >
Kite Pharma's CAR T-Cell Therapy Wins European Approval In Refractory Leukemia Setting
Via Benzinga
Kite’s CAR T-cell Therapy Tecartus® Granted European Marketing Authorization for the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia (r/r ALL)
From Gilead Sciences, Inc.
Via Business Wire
Gilead's Breast Cancer Drug Improves Progression-Free Survival in HR+/HER2- Metastatic Breast Cancer
Via Benzinga
New TROPiCS-02 Data in HR+/HER2- Metastatic Breast Cancer Patients Demonstrates Progression-Free Survival Benefit of Trodelvy® Regardless of Their HER2 Status
From Gilead Sciences, Inc.
Via Business Wire
Raymond James Initiates AnaptysBio With ~42% Upside, Despite Trial Setback
Via Benzinga
What Is Going on With Gilead Sciences (GILD) Stock Today?
GILD stock is the focus of not just one but two news items today, and traders are trying to decide if they're bullish or bearish. 
Via InvestorPlace
Everest Medicines Descends To New Depths On String Of Bad News
Key Takeaways: The CEO of Everest Medicines resigned two days after the company announced its loss grew sharply in the first half of the year The company also lost an important potential new revenue... 
Via Benzinga
Gilead Sciences to Present at Upcoming Investor Conferences
From Gilead Sciences, Inc.
Via Business Wire
Gilead Demonstrates Strength of Oncology Portfolio Across Diverse Tumor Types at ESMO Congress 2022
From Gilead Sciences, Inc.
Via Business Wire
Gilead's Lenacapavir Scores European Approval For Pretreated HIV Patients After Manufacturing Delays
Via Benzinga
Gilead Announces First Global Regulatory Approval of Sunlenca® (Lenacapavir), the Only Twice-Yearly HIV Treatment Option
From Gilead Sciences, Inc.
Via Business Wire
Week In Review: Everest Sells Trodelvy Rights Back To Gilead For $455 Million
Shanghai Everest Medicines returned rights for Trodelvy to Immunomedics, now a subsidiary of Gilead Sciences, in an agreement worth up to $455 million ($280 million upfront). 
Via Talk Markets
10 Health Care Stocks With Whale Alerts In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
Looking For Ebola Virus Meds? WHO Recommends These Two Antibody Treatments
Via Benzinga
Covid Stocks Pfizer, Moderna, Novavax Face Their Next Challenge, And It's Worth Billions
How they handle an upcoming shift in payments will be telling for their tailwind. 
Via Investor's Business Daily
Caribou's Blood Cancer Candidate Shows Response Rates Better Than Novartis,' This Analyst Writes
Via Benzinga
Gilead Sciences Announces Collaboration With Morehouse School of Medicine and Xavier University of Louisiana College of Pharmacy to Address Inequities in HIV Care
From Gilead Sciences, Inc.
Via Business Wire
Can Faraday Future (FFIE) Stock Turn Its Cash Crunch Around?
Faraday Future (FFIE) stock is on the move Tuesday as investors react to news of a new funding agreement to keep the business going. 
Via InvestorPlace
$100 Invested In This Stock 20 Years Ago Would Be Worth $1,400 Today
  Gilead Sciences (NASDAQ:GILD) has outperformed the market over the past 20 years by 6.41% on an annualized basis producing an average annual return of 14.28%. Currently, Gilead Sciences has a market... 
Via Benzinga
SoftBank Just Gave Nu Holdings (NU) Stock a Big Boost
Nu Holdings (NU) stock is on the rise Tuesday as investors react to news of SoftBank (SFTBY) taking a stake in the banking company. 
Via InvestorPlace
After Surprise Overall Survival Data In Metastatic Breast Cancer, Gilead Takes Complete Rights To Trodelvy
Via Benzinga
Gilead to Acquire Remaining Worldwide Rights of Trodelvy®
From Gilead Sciences, Inc.
Via Business Wire
Recap Of Monday's Biotech Catalysts - End Of the Day Summary
Via Benzinga
Why Gilead Sciences Stock Jumped 5% Today
Gilead Sciences Inc (NASDAQ: GILD) shares closed higher Monday after the company announced statistically significant and clinically meaning 
Via Benzinga
Snap, Gilead Sciences And Some Other Big Stocks Moving Higher On Monday
Magic Empire Global Limited (NASDAQ: MEGL) shares climbed 80.9% to $14.87 on volatility following the company's IPO earlier this month. 
Via Benzinga
Gilead Shares Climb On Positive Interim Analysis From Late-Stage Breast Cancer Study
Gilead Sciences, Inc. (NASDAQ: GILD) announced positive results from the second interim analysis of the key secondary endpoint of overall survival (OS) in the Phase 3 TROPiCS-02 study evaluating... 
Via Benzinga
Trodelvy® Significantly Improves Overall Survival in Pre-Treated HR+/HER2- Metastatic Breast Cancer Patients in the TROPiCS-02 Study
From Gilead Sciences, Inc.
Via Business Wire
7 Growth Stocks to Buy After a 20% Correction
These are among the best growth stocks to buy now. ADBE, AMD, GILD, LOW, MELI, MP, and PYPL are poised to benefit from strong trends in 2022. 
Via InvestorPlace
3 Best Funds for Aggressive Investors
These are the three best funds for aggressive investors. ETFs like BUG, RYT, and BBH can make great investments in the rest of the year. 
Via InvestorPlace
Gilead Sciences and a Coalition of LGBTQ+ and Human Rights-Focused Organizations Mobilize to Address Monkeypox Public Health Emergency
From Gilead Sciences, Inc.
Via Business Wire
< Previous 1 2
...
28 29 30 31 32 33 34 35 36
...
52 53 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.